Annual Report

Overview

The report presents Valeo Pharma's FY2023 consolidated financial results for the year ended October 31, 2023. Revenue reached 53,910 thousand Canadian dollars, up 94% from FY2022, while the company reported a net loss of 27,808 thousand Canadian dollars and used 15,695 thousand Canadian dollars in operating cash. The report also highlights the expanded commercial portfolio, including Xiidra, Simbrinza, and Allerject, alongside a going-concern uncertainty.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: Ends 31 October 2023
Publication date: 25 January 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services